137 related articles for article (PubMed ID: 2120548)
41. Studies on hindered phenols and analogues. V. Synthesis, identification, and antidiabetic activity of the glucuronide of CS-045.
Yoshioka T; Aizawa Y; Fujita T; Nakamura K; Sasahara K; Kuwano H; Kinoshita T; Horikoshi H
Chem Pharm Bull (Tokyo); 1991 Aug; 39(8):2124-5. PubMed ID: 1797433
[TBL] [Abstract][Full Text] [Related]
42. Effect of troglitazone, a new oral antidiabetic agent, on fructose-induced insulin resistance.
Yagi N; Takasu N; Higa S; Ishikawa K; Murakami K; Mimura G
Horm Metab Res; 1995 Oct; 27(10):439-41. PubMed ID: 8575720
[TBL] [Abstract][Full Text] [Related]
43. Tissue-specific actions of antidiabetic thiazolidinediones on the reduced fatty acid oxidation in skeletal muscle and liver of Zucker diabetic fatty rats.
Ide T; Nakazawa T; Mochizuki T; Murakami K
Metabolism; 2000 Apr; 49(4):521-5. PubMed ID: 10778879
[TBL] [Abstract][Full Text] [Related]
44. Troglitazone stimulates acetyl-CoA carboxylase activity through a post-translational mechanism.
Thampy GK; Haas MJ; Mooradian AD
Life Sci; 2000 Dec; 68(6):699-708. PubMed ID: 11205884
[TBL] [Abstract][Full Text] [Related]
45. Troglitazone: a review of its use in the management of type 2 diabetes mellitus.
Plosker GL; Faulds D
Drugs; 1999 Mar; 57(3):409-38. PubMed ID: 10193691
[TBL] [Abstract][Full Text] [Related]
46. A new antidiabetic agent, BRL 49653, reduces lipid availability and improves insulin action and glucoregulation in the rat.
Oakes ND; Kennedy CJ; Jenkins AB; Laybutt DR; Chisholm DJ; Kraegen EW
Diabetes; 1994 Oct; 43(10):1203-10. PubMed ID: 7926289
[TBL] [Abstract][Full Text] [Related]
47. An antidiabetic thiazolidinedione potentiates insulin stimulation of glycogen synthase in rat adipose tissues.
Berger J; Biswas C; Hayes N; Ventre J; Wu M; Doebber TW
Endocrinology; 1996 May; 137(5):1984-90. PubMed ID: 8612539
[TBL] [Abstract][Full Text] [Related]
48. Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects.
Suter SL; Nolan JJ; Wallace P; Gumbiner B; Olefsky JM
Diabetes Care; 1992 Feb; 15(2):193-203. PubMed ID: 1547676
[TBL] [Abstract][Full Text] [Related]
49. Metabolic effects of troglitazone in the Goto-Kakizaki rat, a non-obese and normolipidemic rodent model of non-insulin-dependent diabetes mellitus.
O'Rourke CM; Davis JA; Saltiel AR; Cornicelli JA
Metabolism; 1997 Feb; 46(2):192-8. PubMed ID: 9030828
[TBL] [Abstract][Full Text] [Related]
50. Effects of troglitazone on dexamethasone-induced insulin resistance in rats.
Okumura S; Takeda N; Takami K; Yoshino K; Hattori J; Nakashima K; Sugimoto M; Ishimori M; Takami R; Yasuda K
Metabolism; 1998 Mar; 47(3):351-4. PubMed ID: 9500576
[TBL] [Abstract][Full Text] [Related]
51. Acute effects of troglitazone and nitric oxide on glucose uptake in L929 fibroblast cells.
Van Dyke DA; Walters L; Frieswyk D; Kokmeyer D; Louters LL
Life Sci; 2003 Apr; 72(21):2321-7. PubMed ID: 12639698
[TBL] [Abstract][Full Text] [Related]
52. Effect of troglitazone on leptin production. Studies in vitro and in human subjects.
Nolan JJ; Olefsky JM; Nyce MR; Considine RV; Caro JF
Diabetes; 1996 Sep; 45(9):1276-8. PubMed ID: 8772734
[TBL] [Abstract][Full Text] [Related]
53. Acute effects of troglitazone on in vivo insulin action in normal rats.
Lee MK; Olefsky JM
Metabolism; 1995 Sep; 44(9):1166-9. PubMed ID: 7666790
[TBL] [Abstract][Full Text] [Related]
54. Troglitazone.
Spencer CM; Markham A
Drugs; 1997 Jul; 54(1):89-101; discussion 102. PubMed ID: 9211083
[TBL] [Abstract][Full Text] [Related]
55. Troglitazone, an antidiabetic agent, inhibits cholesterol biosynthesis through a mechanism independent of peroxisome proliferator-activated receptor-gamma.
Wang M; Wise SC; Leff T; Su TZ
Diabetes; 1999 Feb; 48(2):254-60. PubMed ID: 10334298
[TBL] [Abstract][Full Text] [Related]
56. Quantification of the effects of troglitazone on insulin sensitivity and beta-cell function in Watanabe heritable hyperlipidemic rabbits: a minimal model analysis.
Zhang B; Saku K; Arakawa K
Metabolism; 1997 Mar; 46(3):273-81. PubMed ID: 9054469
[TBL] [Abstract][Full Text] [Related]
57. Metabolic effects of troglitazone on fructose-induced insulin resistance in the rat.
Lee MK; Miles PD; Khoursheed M; Gao KM; Moossa AR; Olefsky JM
Diabetes; 1994 Dec; 43(12):1435-9. PubMed ID: 7958495
[TBL] [Abstract][Full Text] [Related]
58. Effects of troglitazone and voluntary running on insulin resistance induced high fat diet in the rat.
Kitakoshi K; Oshida Y; Nakai N; Han YQ; Sato Y
Horm Metab Res; 2001 Jun; 33(6):365-9. PubMed ID: 11456287
[TBL] [Abstract][Full Text] [Related]
59. Troglitazone treatment increases protein kinase B phosphorylation in skeletal muscle of normoglycemic subjects at risk for the development of type 2 diabetes.
Meyer MM; Levin K; Grimmsmann T; Perwitz N; Eirich A; Beck-Nielsen H; Klein HH
Diabetes; 2002 Sep; 51(9):2691-7. PubMed ID: 12196460
[TBL] [Abstract][Full Text] [Related]
60. Acute exposure of beta-cells to troglitazone decreases insulin hypersecretion via activating AMPK.
Deng R; Nie A; Jian F; Liu Y; Tang H; Zhang J; Zhang Y; Shao L; Li F; Zhou L; Wang X; Ning G
Biochim Biophys Acta; 2014 Jan; 1840(1):577-85. PubMed ID: 24144566
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
